Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cryo Cell International (CCEL) Cash & Equivalents (2016 - 2026)

Cryo Cell International's Cash & Equivalents history spans 17 years, with the latest figure at $249672.0 for Q1 2026.

  • Quarterly results put Cash & Equivalents at $249672.0 for Q1 2026, up 11.9% from a year ago — trailing twelve months through Feb 2026 was $249672.0 (up 11.9% YoY), and the annual figure for FY2025 was $319031.0, down 43.13%.
  • Cash & Equivalents for Q1 2026 was $249672.0 at Cryo Cell International, down from $319031.0 in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $2.9 million in Q3 2022 to a low of $137491.0 in Q2 2025.
  • The 5-year median for Cash & Equivalents is $469195.0 (2024), against an average of $925536.7.
  • Peak annual rise in Cash & Equivalents hit 38.14% in 2024, while the deepest fall reached 82.0% in 2024.
  • Year by year, Cash & Equivalents stood at $1.7 million in 2022, then crashed by 76.17% to $406067.0 in 2023, then surged by 38.14% to $560960.0 in 2024, then tumbled by 43.13% to $319031.0 in 2025, then dropped by 21.74% to $249672.0 in 2026.
  • According to Business Quant data, Cash & Equivalents over the past three periods came in at $249672.0, $319031.0, and $265207.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.